<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Compared to subcutaneous fat, visceral fat is more metabolically active, leading to <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mp ids='MP_0001845'>inflammation</z:mp> and <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study is to describe the effect of visceral <z:hpo ids='HP_0001513'>obesity</z:hpo> on <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> outcomes using computed tomography (CT) imaging to measure visceral fat </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIALS AND METHODS: We conducted a retrospective chart review of patients who underwent surgical resection for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Visceral fat volume was measured by preoperative CT scans </plain></SENT>
<SENT sid="4" pm="."><plain>Final analysis was performed by stratifying patients based on oncologic stage </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Two hundred nineteen patients met the inclusion criteria, 111 viscerally <z:mp ids='MP_0001261'>obese</z:mp> and 108 nonobese </plain></SENT>
<SENT sid="6" pm="."><plain>Body mass index (BMI) weakly correlated with visceral fat volume measurements (R (2) = 0.304) </plain></SENT>
<SENT sid="7" pm="."><plain>Whereas <z:mp ids='MP_0001261'>obese</z:mp> patients had no difference in survival when categorizing <z:hpo ids='HP_0001513'>obesity</z:hpo> by BMI, categorizing based on visceral fat volume resulted in significant differences in stage II and stage III patients </plain></SENT>
<SENT sid="8" pm="."><plain>In stage II <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, viscerally <z:mp ids='MP_0001261'>obese</z:mp> patients had a nearly threefold decrease in disease-free survival (hazard ratio (HR) = 2.72; 95 % confidence interval (CI) = 1.21, 6.10) </plain></SENT>
<SENT sid="9" pm="."><plain>In stage III <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, viscerally <z:mp ids='MP_0001261'>obese</z:mp> patients had a longer time to recurrence (HR = 0.39; 95 % CI = 0.16, 0.99) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: This study shows that viscerally <z:mp ids='MP_0001261'>obese</z:mp> patients with <z:e sem="disease" ids="C0677948" disease_type="Neoplastic Process" abbrv="">stage II colorectal cancer</z:e> are at higher risk for poor outcomes and should be increasingly considered for adjuvant chemotherapy </plain></SENT>
</text></document>